

Supplemental Table 1a: Comparison of outcomes by risk factors in ACH-associated/ACH-onset CDI cohort and matched controls\*

<i>Cohort</i>	30-day all-cause re-hospitalization		30-day all-cause mortality post-discharge		180-day all-cause mortality post-discharge	
	CDI cohort	Non-CDI cohort	CDI Cohort	Non-CDI cohort	CDI cohort	Non-CDI cohort
<b>N</b>	<b>1,256</b>	<b>141</b>	<b>2,013</b>	<b>10,847</b>	<b>5,595</b>	<b>14,878</b>
<b>Age group (years)</b>						
18-44	**	**	10 (0.5%)	54 (0.5%)	30 (0.5%)	72 (0.5%)
45-64	299 (23.8%)	15 (10.6%)	192 (9.5%)	1,032 (9.5%)	598 (10.7%)	1,408 (9.5%)
65-74	252 (20.1%)	25 (17.7%)	372 (18.5%)	1,862 (17.2%)	1,000 (17.9%)	2,486 (16.7%)
75-84	406 (32.3%)	55 (39.0%)	746 (37.1%)	4,242 (39.1%)	2,130 (38.1%)	5,837 (39.2%)
85+	242 (19.3)	45 (31.9%)	693 (34.4%)	3,657 (33.7%)	1,837 (32.8%)	5,075 (34.1%)
<b>Sex</b>						
Female	620 (49.4%)	74 (52.5%)	990 (49.2%)	5,256 (48.5%)	2,783 (49.7%)	7,309 (49.1%)
Male	636 (50.6%)	67 (47.5%)	1,023 (50.8%)	5,591 (51.5%)	2,812 (50.3%)	7,569 (50.9%)
<b>LTCF resident</b>	64 (5.1%)	21 (14.9%)	204 (10.1%)	1,677 (15.5%)	429 (7.7%)	2,186 (14.7%)
<b>Healthcare exposure in 90 days prior to onset</b>	483 (38.5%)	60 (42.6%)	764 (38.0%)	3,578 (33.0%)	2,094 (37.4%)	4,952 (33.3%)
<b>Healthcare exposure in year prior to onset</b>	742 (59.1%)	83 (58.9%)	1,107 (55.0%)	5,633 (51.9%)	3,053 (54.6%)	7,770 (52.2%)
<b>Antibiotic use in 30 days prior to onset</b>	312 (24.8%)	37 (26.2%)	621 (30.8%)	2,596 (23.9%)	1,614 (28.8%)	3,482 (23.4%)
<b>Comorbidities</b>						
CVD	850 (67.7%)	106 (75.2%)	1,380 (68.6%)	7,453 (68.7%)	3,847 (68.8%)	10,220 (68.7%)
COPD	153 (12.2%)	16 (11.3%)	278 (13.8%)	1,528 (14.1%)	696 (12.4%)	2,044 (13.7%)
CHF	280 (22.3%)	29 (20.6%)	441 (21.9%)	2,301 (21.2%)	1,197 (21.4%)	3,134 (21.1%)
Diabetes	123	9	185	966	512	1,332

	(9.8%)	(6.4%)	(9.2%)	(8.9%)	(9.2%)	(9.0%)
Renal disease	299 (23.8%)	39 (27.7%)	477 (23.7%)	1,947 (17.9%)	1,329 (23.8%)	2,659 (17.9%)
Liver disease	94 (7.5%)	6 (4.3%)	131 (6.5%)	554 (5.1%)	335 (6.0%)	739 (5.0%)
Cancer	223 (17.8%)	24 (17.0%)	369 (18.3%)	2,264 (20.9%)	1,036 (18.5%)	3,222 (21.7%)
Pulmonary circulatory disorder	53 (4.2%)	9 (6.4%)	86 (4.3%)	404 (3.7%)	218 (3.9%)	594 (4.0%)
Valvular disease	96 (7.6%)	7 (5.0%)	134 (6.7%)	714 (6.6%)	362 (6.5%)	962 (6.5%)
Inflammatory bowel disease	**	**	57 (2.8%)	203 (1.9%)	136 (2.4%)	280 (1.9%)

\*Shaded cells denote statistically significant differences ( $p$ -value  $\leq 0.05$ ) between the CDI cohort and their matched controls

\*\* Exact counts were low, and therefore withheld from analysis due to privacy concerns

Supplemental Table 1b: Risk factors for all-cause re-hospitalization and mortality in ACH-associated/ACH-onset CDI cohort\*

	30-day all-cause re-hospitalization		30-day all-cause mortality post-discharge		180-day all-cause mortality post-discharge	
	OR	P-Value	OR	P-Value	OR	P-Value
<b>Age group (years)</b>						
18-44 vs 85+	2.15 (1.59, 2.92)	<.0001	0.10 (0.07, 1.16)	<.0001	0.14 (0.10, 0.20)	<.0001
45-64 vs 85+	1.87 (1.56, 2.23)	<.0001	0.42 (0.38, 0.47)	<.0001	0.47 (0.43, 0.52)	<.0001
65-74 vs 85+	1.24 (1.04, 1.49)	0.0178	0.60 (0.55, 0.65)	<.0001	0.63 (0.58, 0.68)	<.0001
75-84 vs 85+	1.16 (0.99, 1.37)	0.065	0.79 (0.74, 0.84)	<.0001	0.81 (0.76, 0.86)	<.0001
<b>Sex (reference: male)</b>	0.99 (0.89, 1.11)	0.88	0.85 (0.80, 0.90)	<.0001	0.88 (0.83, 0.92)	<.0001
<b>LTCF resident</b>	1.07 (0.83, 1.39)	0.58	1.21 (1.08, 1.35)	0.0009	1.26 (1.14, 1.39)	<.0001
<b>Healthcare exposure in 90 days prior to onset</b>	0.99 (0.85, 1.15)	0.86	1.14 (1.04, 1.24)	0.0032	1.14 (1.05, 1.22)	0.0009
<b>Healthcare exposure in year prior to onset</b>	1.32 (1.13, 1.54)	0.0005	1.00 (0.92, 1.09)	0.92	1.01 (0.94, 1.09)	0.83
<b>Antibiotic use in 30 days prior to onset</b>	0.93 (0.81, 1.06)	0.25	1.09 (1.02, 1.16)	0.014	1.09 (1.03, 1.16)	0.003
<b>Comorbidities</b>						
CVD	1.16 (1.02, 1.34)	0.029	0.99 (0.93, 1.06)	0.84	1.00 (0.94, 1.07)	0.93
COPD	0.99 (0.83, 1.17)	0.89	1.04 (0.96, 1.14)	0.35	1.02 (0.94, 1.10)	0.61
CHF	1.26 (1.09, 1.46)	0.0019	1.08 (1.00, 1.16)	0.045	1.09 (1.02, 1.17)	0.0094
Diabetes	0.99 (0.82, 1.20)	0.93	0.97 (0.88, 1.07)	0.54	1.00 (0.92, 1.09)	0.99
Renal disease	1.16 (1.01, 1.33)	0.036	1.16 (1.08, 1.25)	<.0001	1.17 (1.10, 1.24)	<.0001
Liver disease	1.21 (0.97, 1.49)	0.089	1.39 (1.23, 1.57)	<.0001	1.34 (1.20, 1.50)	<.0001
Cancer	1.08 (0.93, 1.25)	0.32	1.17 (1.08, 1.27)	<.0001	1.24 (1.16, 1.33)	<.0001
Pulmonary circulatory disorder	1.17 (0.88, 1.54)	0.28	1.13 (0.97, 1.31)	0.13	1.16 (1.02, 1.32)	0.028
Valvular disease	1.30 (1.05, 1.61)	0.017	1.03 (0.91, 1.16)	0.66	1.05 (0.94, 1.17)	0.38
Inflammatory bowel disease	1.21 (0.91, 1.59)	0.18	0.79 (0.66, 0.96)	0.018	0.85 (0.72, 0.99)	0.049

\*Shaded cells denote the statistical significance (p-value ≤ 0.05) of ORs

Supplemental Table 2a: Comparison of outcomes by risk factors in LTCF-associated/LTCF-onset CDI cohort and matched controls\*\*~

Cohort	30-day all-cause mortality post-admission		180-day all-cause mortality post-admission	
	CDI cohort	Non-CDI cohort	CDI cohort	Non-CDI cohort
<b>N</b>	<b>234</b>	<b>59</b>	<b>333</b>	<b>173</b>
<b>Age group (years)</b>				
18-44	0 (0%)	0 (0.0%)	0 (0.0%)	0 (0%)
45-64	**	0 (0%)	**	0 (0%)
65-74	13 (5.6%)	**	19 (5.7%)	8 (4.6%)
75-84	70 (29.9%)	19 (32.2%)	101 (30.3%)	55 (31.8%)
85+	149 (63.7%)	37 (62.7%)	211 (63.4%)	101 (58.4%)
<b>Sex</b>				
Female	157 (67.1%)	39 (66.1%)	218 (65.5%)	101 (58.4%)
Male	77 (32.9%)	20 (33.9%)	115 (34.5%)	72 (41.6%)
Healthcare exposure in 90 days prior to onset	6 (2.6%)	**	10 (3.0%)	**
Healthcare exposure in year prior to onset	107 (45.7%)	20 (33.9%)	150 (45.0%)	55 (31.8%)
Antibiotic use in 30 days prior to onset	68 (29.1%)	**	92 (27.6%)	8 (4.6%)
<b>Comorbidities</b>				
CVD	168 (71.8%)	48 (81.4%)	234 (70.3%)	124 (71.7%)
COPD	29 (12.4%)	11 (18.6%)	45 (13.5%)	26 (15.0%)
CHF	45 (19.2%)	14 (23.7%)	62 (18.6%)	40 (23.1%)
Diabetes	21 (9.0%)	7 (11.9%)	35 (10.5%)	16 (9.2%)
Renal disease	41	15	56	26

	(17.5%)	(25.4%)	(16.8%)	(15.0%)
Liver disease	8 (3.4%)	**	13 (3.9%)	**
Cancer	7 (3.0%)	**	14 (4.2%)	17 (9.8%)
Pulmonary circulatory disorder	7 (3.0%)	0 (0%)	9 (2.7%)	0 (0%)
Valvular disease	**	**	8 (2.4%)	11 (6.4%)
Inflammatory bowel disease	**	**	8 (2.4%)	**

\*Shaded cells denote statistically significant differences (p-value  $\leq 0.05$ ) between the CDI cohort and their matched controls

\*\*Exact counts were low, and therefore withheld from analysis due to privacy concerns

~Results for 30-day all-cause re-hospitalization are not displayed due to low numbers

Supplementary Table 2b: Risk factors for all-cause re-hospitalization and mortality in LTCF-associated/LTCF-onset CDI cohort\*

	30-day all-cause re-hospitalization		30-day all-cause mortality post-admission		180-day all-cause mortality post-admission	
	OR	P-Value	OR	P-Value	OR	P-Value
<b>Age group (years)</b>						
18-44 vs 85+	-	-	0.48 (0.12, 1.99)	0.31	0.33 (0.08, 1.35)	0.12
45-64 vs 85+	1.86 (0.75, 4.59)	0.18	0.63 (0.35, 1.11)	0.11	0.63 (0.39, 1.01)	0.056
65-74 vs 85+	0.67 (0.30, 1.52)	0.34	0.82 (0.61, 1.09)	0.18	0.82 (0.64, 1.04)	0.10
75-84 vs 85+	-	-	-	-	-	-
<b>Sex (reference: male)</b>	0.45 (0.22, 0.90)	0.025	0.98 (0.74, 1.30)	0.89	0.90 (0.71, 1.14)	0.38
<b>Healthcare exposure in 90 days prior to onset</b>	-	-	1.39 (0.66, 2.90)	0.38	1.29 (0.67, 2.48)	0.45
<b>Healthcare exposure in year prior to onset</b>	0.87 (0.43, 1.75)	0.60	1.05 (0.80, 1.39)	0.71	1.04 (0.82, 1.31)	0.75
<b>Antibiotic use in 30 days prior to onset</b>	1.24 (0.60, 2.57)	0.55	1.02 (0.77, 1.37)	0.88	0.99 (0.77, 1.26)	0.91
<b>Comorbidities</b>						
CVD	1.36 (0.59, 3.10)	0.47	1.16 (0.85, 1.58)	0.35	1.07 (0.83, 1.39)	0.59
COPD	0.38 (0.09, 1.61)	0.19	0.90 (0.60, 1.34)	0.62	0.99 (0.72, 1.37)	0.96
CHF	1.03 (0.44, 2.42)	0.94	0.98 (0.69, 1.41)	0.94	0.98 (0.72, 1.32)	0.88
Diabetes	1.60 (0.65, 3.97)	0.31	0.78 (0.49, 1.22)	0.27	0.94(0.66, 1.34)	0.72
Renal disease	1.03 (0.43, 2.48)	0.94	1.03 (0.72, 1.48)	0.86	0.97 (0.71, 1.32)	0.85
Liver disease	1.97 (0.54, 7.11)	0.30	1.16 (0.60, 2.25)	0.66	1.00 (0.55, 1.81)	0.99
Cancer	1.03 (0.22, 4.78)	0.97	0.83 (0.41, 1.71)	0.62	0.99 (0.57, 1.71)	0.97
Pulmonary circulatory disorder	2.50 (0.83, 7.53)	0.10	0.92 (0.43, 1.98)	0.83	0.85 (0.43, 1.67)	0.64
Valvular disease	1.88 (0.23, 15.25)	0.55	1.09 (0.43, 2.75)	0.86	1.36 (0.65, 2.84)	0.41
Inflammatory bowel disease	0.90 (0.10, 7.98)	0.93	0.64 (0.23, 1.75)	0.38	0.86 (0.41, 1.77)	0.68

\*Shaded cells denote the statistical significance (p-value ≤ 0.05) of ORs

Supplemental Table 3a: Comparison of outcomes by risk factors in community-associated/community-onset CDI cohort and matched controls\*

Cohort	30-day all-cause re-hospitalization		30-day all-cause mortality post-admission		180-day all-cause mortality post-admission	
	CDI cohort	Non-CDI cohort	CDI cohort	Non-CDI cohort	CDI cohort	Non-CDI cohort
<b>N</b>	<b>554</b>	<b>175</b>	<b>1,253</b>	<b>199</b>	<b>2,197</b>	<b>653</b>
<b>Age group (years)</b>						
18-44	**	**	15 (1.2%)	0 (0.0%)	**	**
45-64	124 (22.4%)	19 (10.9%)	122 (9.7%)	15 (7.5%)	255 (11.6%)	58 (8.9%)
65-74	129 (23.3%)	31 (17.7%)	210 (16.8%)	31 (15.6%)	358 (16.3%)	98 (15.0%)
75-84	146 (26.4%)	66 (37.7%)	418 (33.3%)	48 (24.1%)	721 (32.8%)	170 (26.0%)
85+	105 (19.0%)	55 (31.4%)	488 (38.9%)	105 (52.8%)	833 (37.9%)	326 (49.9%)
<b>Sex</b>						
Female	309 (55.8%)	92 (52.6%)	718 (57.3%)	109 (54.8%)	1,236 (56.3%)	361 (55.3%)
Male	245 (44.2%)	83 (47.4%)	535 (42.7%)	90 (45.2%)	961 (43.7%)	292 (44.7%)
<b>Healthcare exposure in 90 days prior to onset</b>						
	**	**	**	**	52 (2.4%)	12 (1.8%)
<b>Healthcare exposure in year prior to onset</b>						
	232 (41.9%)	67 (38.3%)	495 (39.5%)	91 (45.7%)	870 (39.6%)	279 (42.7%)
<b>Antibiotic use in 30 days prior to onset</b>						
	102 (18.4%)	20 (11.4%)	323 (25.8%)	24 (12.1%)	501 (22.8%)	63 (9.6%)
<b>Comorbidities</b>						
CVD	319 (57.6%)	132 (75.4%)	838 (66.9%)	152 (76.4%)	1,426 (64.9%)	472 (72.3%)
COPD	59 (10.6%)	28 (16.0%)	175 (14.0%)	27 (13.6%)	290 (13.2%)	87 (13.3%)
CHF	84 (15.2%)	30 (17.1%)	248 (19.8%)	49 (24.6%)	417 (19.0%)	150 (23.0%)
Diabetes	60 (10.8%)	16 (9.1%)	89 (7.1%)	16 (8.0%)	177 (8.1%)	53 (8.1%)
Renal disease	132	40	267	49	464	133

	(23.8%)	(22.9%)	(21.3%)	(24.6%)	(21.1%)	(20.4%)
Liver disease	57 (10.3%)	13 (7.4%)	78 (6.2%)	15 (7.5%)	142 (6.5%)	39 (6.0%)
Cancer	98 (17.7%)	27 (15.4%)	221 (17.6%)	69 (34.7%)	415 (18.9%)	185 (28.3%)
Pulmonary circulatory disorder	20 (3.6%)	12 (6.9%)	45 (3.6%)	15 (7.5%)	77 (3.5%)	44 (6.7%)
Valvular disease	21 (3.8%)	13 (7.4%)	61 (4.9%)	10 (5.0%)	103 (4.7%)	41 (6.3%)
Inflammatory bowel disease	**	**	51 (4.1%)	6 (3.0%)	96 (4.4%)	9 (1.4%)

\*Shaded cells denote statistically significant differences ( $p$ -value  $\leq 0.05$ ) between the CDI cohort and their matched controls

\*\* Exact counts were low, and therefore withheld from analysis due to privacy concerns



**Supplementary Table 3b: Risk factors for all-cause re-hospitalization and mortality in community-associated/community-onset CDI cohort\***

	30-day all-cause re-hospitalization		30-day all-cause mortality post-admission		180-day all-cause mortality post-admission	
	OR	P-Value	OR	P-Value	OR	P-Value
<b>Age group (years)</b>						
18-44 vs 85+	1.08 (0.75, 1.56)	0.68	0.08 (0.05, 1.34)	<.0001	0.09 (0.06, 0.13)	<.0001
45-64 vs 85+	1.13 (0.86, 1.48)	0.39	0.25 (0.21, 0.31)	<.0001	0.30 (0.26, 0.34)	<.0001
65-74 vs 85+	1.35 (1.03, 1.75)	0.027	0.49 (0.42, 0.58)	<.0001	0.47 (0.42, 0.54)	<.0001
75-84 vs 85+	1.08 (0.84, 1.39)	0.54	0.68 (0.60, 0.78)	<.0001	0.67 (0.61, 0.75)	<.0001
<b>Sex (reference: male)</b>						
	0.94 (0.79, 1.11)	0.47	0.87 (0.77, 0.97)	0.013	0.84 (0.77, 0.91)	<.0001
<b>Healthcare exposure in 90 days prior to onset</b>						
	1.00 (0.57, 1.75)	1.00	1.07 (0.75, 1.53)	0.71	1.02 (0.77, 1.34)	0.91
<b>Healthcare exposure in year prior to onset</b>						
	1.32 (1.10, 1.59)	0.0029	1.17 (1.03, 1.32)	0.012	1.19 (1.08, 1.30)	0.0003
<b>Antibiotic use in 30 days prior to onset</b>						
	0.84 (0.67, 1.04)	0.11	1.15 (1.01, 1.31)	0.032	0.99 (0.89, 1.09)	0.82
<b>Comorbidities</b>						
CVD	1.00 (0.82, 1.22)	1.00	1.06 (0.93, 1.21)	0.36	1.00 (0.90, 1.10)	0.98
COPD	0.91 (0.69, 1.20)	0.50	1.22 (1.04, 1.44)	0.015	1.15 (1.01, 1.30)	0.03
CHF	1.03 (0.80, 1.33)	0.82	1.11 (0.95, 1.29)	0.19	1.09 (0.97, 1.23)	0.13
Diabetes	1.30 (0.99, 1.70)	0.058	0.82 (0.66, 1.01)	0.067	0.94 (0.81, 1.10)	0.44
Renal disease	1.38 (1.12, 1.70)	0.0022	1.02 (0.88, 1.17)	0.83	1.03 (0.92, 1.14)	0.65
Liver disease	1.57 (1.19, 2.09)	0.0016	1.38 (1.09, 1.74)	0.0078	1.39 (1.16, 1.65)	0.0002
Cancer	1.37 (1.10, 1.72)	0.0058	1.51 (1.31, 1.76)	<.0001	1.62 (1.45, 1.81)	<.0001
Pulmonary circulatory disorder	1.22 (0.77, 1.92)	0.40	1.19 (0.88, 1.60)	0.27	1.17 (0.93, 1.48)	0.18
Valvular disease	1.02 (0.65, 1.60)	0.92	1.14 (0.87, 1.48)	0.34	1.12 (0.91, 1.37)	0.27
Inflammatory bowel disease	1.15 (0.86, 1.53)	0.35	0.66 (0.50, 0.87)	0.0038	0.69 (0.56, 0.85)	0.0004

\*\*\*Shaded cells denote the statistical significance (p-value ≤ 0.05) of ORs

Supplemental Table 4a: Comparison of outcomes by risk factors in ACH-associated/community-onset CDI cohort and matched controls\*\*

Cohort	All-cause 30-day re-hospitalization		30-day mortality		180-day mortality	
	CDI cohort	Non-CDI cohort	CDI cohort	Non-CDI cohort	CDI cohort	Non-CDI cohort
<b>N</b>	<b>202</b>	<b>26</b>	<b>637</b>	<b>1,758</b>	<b>1,024</b>	<b>2,392</b>
<b>Age group (years)</b>						
18-44	5 (2.5%)	3 (11.5%)	**	**	6 (0.6%)	19 (0.8%)
45-64	69 (34.2%)	3 (11.5%)	78 (12.2%)	233 (13.3%)	144 (14.1%)	311 (13.0%)
65-74	54 (26.7%)	3 (11.5%)	127 (19.9%)	390 (22.2%)	234 (22.9%)	530 (22.2%)
75-84	57 (28.2%)	14 (53.8%)	255 (40.0%)	681 (38.7%)	384 (37.5%)	942 (39.4%)
85+	17 (8.4%)	3 (11.5%)	176 (27.6%)	443 (25.2%)	256 (25.0%)	590 (24.7%)
<b>Sex</b>						
Female	106 (52.5%)	13 (50.0%)	305 (47.9%)	812 (46.2%)	480 (46.9%)	1,108 (46.3%)
Male	96 (47.5%)	13 (50.0%)	332 (52.1%)	946 (53.8%)	544 (53.1%)	1,284 (53.7%)
Antibiotic use in 30 days prior to onset	89 (44.1%)	9 (34.6%)	326 (51.2%)	649 (36.9%)	506 (49.4%)	872 (36.5%)
<b>Comorbidities</b>						
CVD	151 (74.8%)	20 (76.9%)	515 (80.8%)	1,354 (77.0%)	813 (79.4%)	1,833 (76.6%)
COPD	36 (17.8%)	6 (23.1%)	115 (18.1%)	269 (15.3%)	179 (17.5%)	359 (15.0%)
CHF	47 (23.3%)	8 (30.8%)	181 (28.4%)	492 (28.0%)	275 (26.9%)	644 (26.9%)
Diabetes	22 (10.9%)	3 (11.5%)	75 (11.8%)	203 (11.5%)	119 (11.6%)	277 (11.6%)
Renal disease	56 (22.7%)	3 (11.5%)	200 (31.4%)	459 (26.1%)	327 (31.9%)	608 (25.4%)
Liver disease	27 (13.4%)	3 (11.5%)	46 (7.2%)	144 (8.2%)	77 (7.5%)	188 (7.9%)
Cancer	48	8	183	630	304	877

	(23.8%)	(30.8%)	(28.7%)	(35.8%)	(29.7%)	(35.4%)
Pulmonary circulatory disorder	12 (5.9%)	3 (11.5%)	54 (8.5%)	132 (7.5%)	74 (7.2%)	171 (7.1%)
Valvular disease	11 (5.4%)	3 (11.5%)	59 (9.3%)	142 (8.1%)	92 (9.0%)	187 (7.8%)
Inflammatory bowel disease	18 (8.9%)	0 (0%)	32 (5.0%)	61 (3.5%)	50 (4.9%)	83 (3.5%)

\*Italicized cells denote statistically significant differences (p-value ≤ 0.05) between the CDI cohort and their matched controls

\*\* Exact counts were low, and therefore withheld from analysis due to privacy concerns

**Supplementary Table 4b: Risk factors for all-cause re-hospitalization and mortality in ACH-associated/community-onset CDI cohort\***

	30-day all-cause re-hospitalization		30-day all-cause mortality post-admission		180-day all-cause mortality post-admission	
	OR	P-Value	OR	P-Value	OR	P-Value
<b>Age group (years)</b>						
18-44 vs 85+	2.69 (1.04, 6.95)	0.04	0.04 (0.006, 0.29)	0.0014	0.16 (0.07, 0.38)	<.0001
45-64 vs 85+	4.62 (2.66, 8.03)	<.0001	0.46 (0.35, 0.61)	<.0001	0.57 (0.46, 0.71)	<.0001
65-74 vs 85+	2.77 (1.58, 4.84)	0.0004	0.58 (0.46, 0.74)	<.0001	0.73 (0.61, 0.87)	0.0007
75-84 vs 85+	2.10 (1.22, 3.64)	0.0078	0.83 (0.68, 1.01)	0.065	0.85 (0.72, 1.00)	0.047
<b>Sex (reference: male)</b>	1.20 (0.91, 1.60)	0.20	0.90 (0.77, 1.06)	0.20	0.88 (0.78, 1.00)	0.046
<b>Antibiotic use in 30 days prior to onset</b>	1.00 (0.76, 1.33)	0.99	1.10 (0.94, 1.29)	0.23	1.05 (0.92, 1.19)	0.47
<b>Comorbidities</b>						
CVD	1.19 (0.83, 1.70)	0.34	1.03 (0.83, 1.27)	0.80	1.01 (0.85, 1.19)	0.94
COPD	1.04 (0.72, 1.50)	0.83	1.03 (0.84, 1.26)	0.80	1.01 (0.86, 1.19)	0.91
CHF	1.06 (0.75, 1.50)	0.75	1.05 (0.87, 1.26)	0.62	1.01 (0.87, 1.17)	0.87
Diabetes	1.06 (0.68, 1.64)	0.79	1.12 (0.87, 1.42)	0.38	1.10 (0.91, 1.33)	0.34
Renal disease	1.03 (0.74, 1.42)	0.87	1.09 (0.92, 1.30)	0.32	1.15 (1.00, 1.31)	0.048
Liver disease	1.57 (1.04, 2.37)	0.031	1.13 (0.84, 1.54)	0.42	1.13 (0.89, 1.42)	0.33
Cancer	0.89 (0.64, 1.24)	0.50	1.40 (1.17, 1.67)	0.0002	1.40 (1.22, 1.61)	<.0001
Pulmonary circulatory disorder	1.20 (0.67, 2.12)	0.54	1.55 (1.16, 2.06)	0.0027	1.31 (1.03, 1.66)	0.029
Valvular disease	0.98 (0.54, 1.75)	0.93	1.05 (0.79, 1.39)	0.73	1.09 (0.87, 1.36)	0.45
Inflammatory bowel disease	1.21 (0.73, 2.01)	0.47	0.96 (0.67, 1.38)	0.84	0.88 (0.66, 1.17)	0.39

\*Shaded cells denote the statistical significance (p-value ≤ 0.05) of ORs